Regional blood flows and cardiac function changes induced by angiotensin II in conscious dogs. 1988

M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
Department of Anesthesiology, Baylor College of Medicine, Houston, Texas.

Hemodynamic properties of angiotensin (ANG) II 1, 5, 10 and 100 ng/kg i.v. and 10, 100 and 1000 ng/kg i.v.t. were assessed in conscious dogs. ANG II i.v. produced a dose-dependent pressor response (59 +/- 5-124 +/- 16 mmHg) and renal vasoconstriction (1.3 +/- 0.4-96 +/- 32 mmHg/ml/min). Ganglionic blockade (chlorisondamine 2 mg/kg i.v.) diminished mean arterial responses without altering peptide effects on renal circulation. At the highest dose, ANG II i.v. induced cardiac stimulation: increased heart rate (75 +/- 4-115 +/- 6 beats/min), cardiac output (2.0 +/- 0.1-2.4 +/- 0.2 l/min), dP/dt (2308 +/- 181-2773 +/- 173 mmHg/sec) and coronary blood flow (49 +/- 10-96 +/- 23 ml/min). Although with chlorisondamine cardiac response was more pronounced, subsequent beta blockade abolished it. Concomitantly, an isolated increase in plasma epinephrine was recorded (63 +/- 8-1505 +/- 354 pg/ml). A pressor response (59 +/- 8-89 +/- 13 mmHg) and renal vasoconstriction (1.1 +/- 0.1-2.2 +/- 0.5 mmHg/ml/min) were also produced by ANG II i.v.t. at the highest dose. These centrally mediated changes were prevented by chlorisondamine. Our study demonstrates 1) i.v. ANG II-mediated pressor responses are dependent on direct and indirect components, the relative contribution of each being dependent on the regional circulation; ANG II i.v. also produced a biphasic cardiac response--an initial centrally mediated depression and a secondary stimulation dependent on epinephrine via cardiac beta receptors and 2) i.v.t. ANG II-mediated pressor effects are essentially indirect. Finally, no evidence was found to support the role of vasopressin in ANG II effects.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D012079 Renal Circulation The circulation of the BLOOD through the vessels of the KIDNEY. Kidney Circulation,Renal Blood Flow,Circulation, Kidney,Circulation, Renal,Blood Flow, Renal,Flow, Renal Blood
D002714 Chlorisondamine A nicotinic antagonist used primarily as a ganglionic blocker in animal research. It has been used as an antihypertensive agent but has been supplanted by more specific drugs in most clinical applications. Chlorisondamine Chloride,Chlorisondamine Dichloride,Ecolid,Chloride, Chlorisondamine,Dichloride, Chlorisondamine
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004837 Epinephrine The active sympathomimetic hormone from the ADRENAL MEDULLA. It stimulates both the alpha- and beta- adrenergic systems, causes systemic VASOCONSTRICTION and gastrointestinal relaxation, stimulates the HEART, and dilates BRONCHI and cerebral vessels. It is used in ASTHMA and CARDIAC FAILURE and to delay absorption of local ANESTHETICS. Adrenaline,4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol,Adrenaline Acid Tartrate,Adrenaline Bitartrate,Adrenaline Hydrochloride,Epifrin,Epinephrine Acetate,Epinephrine Bitartrate,Epinephrine Hydrochloride,Epinephrine Hydrogen Tartrate,Epitrate,Lyophrin,Medihaler-Epi,Acetate, Epinephrine
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
March 1978, The American journal of physiology,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
November 1978, The Journal of clinical investigation,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
November 1976, The American journal of physiology,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
July 2003, Journal of cardiovascular pharmacology,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
December 1986, European journal of clinical investigation,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
January 1975, Indian journal of physiology and pharmacology,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
October 1988, The American journal of physiology,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
February 1977, Circulation research,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
September 1978, The American journal of physiology,
M F Doursout, and J E Chelly, and C J Hartley, and J Szilagyi, and J L Montastruc, and J P Buckley
June 1982, The Journal of clinical investigation,
Copied contents to your clipboard!